



HE Minister Saira Afzal Tarar  
Ministry of National Health Services, Regulations and Coordination  
Government of Pakistan

22 December 2017

***2018 Renewal of Gavi vaccine support***

Honorable Minister,

I am writing with regard to Pakistan's request for the renewal of Gavi support to the Inactivated Polio Vaccine, Pneumococcal, Pentavalent and Rotavirus vaccines which were reviewed by Gavi High Level Review Panel in October 2017.

The attached Appendices include the following important information:

- Appendix A: Financial and Programatic information – Support for Inactivated Polio Vaccine (IPV)
- Appendix B: Financial and Programatic information – Support for Pneumococcal Vaccine (PCV)
- Appendix C: Financial and Programatic information – Support for Pentavalent Vaccine
- Appendix D: Financial and Programatic information – Support for Rotavirus Vaccine
- Appendix E: Financial and Programatic information – Support for Injection Safety Devices

As Pakistan plans to switch PVC from 2-dose to 4-dose vials in 2018, the country is eligible for a product switch grant estimated at USD1.734.942 (Birth Cohort \* 0.25\$). A timeline for the switch and budget in the standard Gavi template and workplan is requested within 60 days of this Decision Letter to enable us to approve the grant and inform the procurement agency regarding the timelines.

Please do not hesitate to contact my colleague Dr. Hamidreza Setayesh ([hsetayesh@gavi.org](mailto:hsetayesh@gavi.org)) if you have any questions or concerns.

Yours sincerely,

A handwritten signature in blue ink that reads "Hind Khatib".

Hind Khatib-Othman  
Managing Director, Country Programmes

cc: The Minister of Finance  
The EPI Manager  
WHO Country Representative  
UNICEF Country Representative  
Regional Working Group  
WHO HQ  
UNICEF Programme Division  
UNICEF Supply Division

**Decision Letter**  
**Financial and Programmatic information: Support for Inactivated Polio Vaccine (IPV)**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Pakistan				
<b>2. Grant number(s):</b> 1518-PAK-25c-X / 15-PAK-08h-Y				
<b>3. Date of Decision Letter:</b> 22/12/2017				
<b>4. Date of the Partnership Framework Agreement:</b> 19/05/2015				
<b>5. Programme title:</b> New Vaccine Support (NVS), IPV routine				
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)				
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 10 doses per vial, LIQUID				
<b>8. Programme duration<sup>2</sup>:</b> 2015 - 2018				
<b>9. Indicative Programme Budget:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>				
	<b>2015-2016</b>	<b>2017</b>	<b>2018</b>	<b>Total<sup>3</sup></b>
<b>Routine Programme (US\$)</b>	6,123,580 <sup>4</sup>	5,291,000	6,964,000	18,378,580
<b>10. Vaccine introduction grant / Product switch grant:</b> Total vaccine introduction grant of US\$ 3,420,894 was disbursed on 10 April 2015 (US\$ 2,696,479) and 29 June 2015 (US\$ 724,415)				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>5</sup>				
	<b>2015-2017</b>		<b>2018</b>	
<b>Number of vaccines to be purchased with Gavi funds</b>				
IPV Routine Programme (doses)			8,396,800	
Annual Amounts (US\$)	11,414,580		6,964,000	
<b>12. Procurement agency:</b> UNICEF.				
<b>13. Self-procurement:</b> Not applicable				
<b>14. Co-financing obligations:</b> Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Pakistan is encouraged to contribute to vaccine and/or supply costs for IPV.				
<b>15. Operational support for catch-up campaigns:</b> Not applicable				
<b>16. Additional reporting requirements:</b>				
<b>Reports and other information</b>				<b>Due dates</b>
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.				15 May

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2018.

<sup>4</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>5</sup> This is the amount that Gavi has approved. The annual amount for 2017 has been amended.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<p><b>18. Other conditions:</b></p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Pakistan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Pakistan.</p>	

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 December 2017

Decision Letter

Financial and Programmatic information: Support for Pneumococcal Vaccine (PCV)

This Decision Letter sets out the Programme Terms of a Programme.

1. <b>Country:</b> Pakistan				
2. <b>Grant number:</b> 1718-PAK-12b-X / 10-PAK-08b-Y				
3. <b>Date of Decision Letter:</b> 22/12/2017				
4. <b>Date of the Partnership Framework Agreement:</b> 19/05/2015				
5. <b>Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine				
6. <b>Vaccine type:</b> Pneumococcal				
7. <b>Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 2 doses per vial, LIQUID, (PCV10), 4 doses per vial, LIQUID				
8. <b>Programme duration<sup>6</sup>:</b> 2011 -2018				
9. <b>Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)				
	<b>2011 - 2016</b>	<b>2017</b>	<b>2018</b>	<b>Total<sup>7</sup></b>
<b>Programme Budget (US\$)</b>	320,628,605 <sup>8</sup>	45,933,000	53,900,000	420,461,605
10. <b>Vaccine introduction grant (in US\$) / Product switch grant:</b> Total vaccine introduction grant of US\$ 4,839,500 was on 26 May 2011 (US\$ 1,783,000) and 29 October 2012 (US\$ 3,056,500) paid				
11. <b>Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>9</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2011-2016</b>	<b>2017</b>	<b>2018</b>	
Number of Pneumococcal vaccine doses		14,920,400	15,646,400	
Annual Amounts (US\$)	320,628,605 <sup>10</sup>	45,933,000	53,900,000	
12. <b>Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. <b>Self-procurement:</b> Not applicable.				
14. <b>Co-financing obligations:</b> Reference code: 1718-PAK-12b-X-C				
<p>According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. Following the approved Country Tailored Approach for Pakistan that allows the alignment of timings of country's co-financing requirements with its fiscal year, Pakistan is required to fulfill the following obligations covering fiscal year 2017/2018 at the latest by 30<sup>th</sup> of June 2018 and 2018/2019 by the 30<sup>th</sup> of June 2019.</p>				
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>FY2017/2018</b>	<b>FY2018/2019</b>		

<sup>6</sup> This is the entire duration of the Programme.

<sup>7</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>8</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>9</sup> This is the amount that Gavi has approved. The 2017 doses were amended.

<sup>10</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Number of vaccine doses	5,998,600	4,710,400
Number of AD syringes	6,043,700	4,652,000
Number of safety boxes	66,500	51,175
Value of vaccine doses (US\$)	18,295,191	\$14,366,640
<b>Total co-financing payments (US\$) (including freight)</b>	<b>\$18,771,000</b>	<b>\$14,782,500</b>
<b>15. Operational support for campaigns:</b> Not applicable		
<b>16. Additional reporting requirements:</b> Not applicable		
<b>Reports and other information</b>	<b>Due dates</b>	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
<b>17. Financial clarifications:</b> Not applicable		
<b>18. Other conditions:</b> Not applicable		

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 December 2017

**Decision Letter**  
**Financial and Programmatic information: Support for Pentavalent Vaccine**

**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Pakistan				
<b>2. Grant number:</b> 1718-PAK-04a-X / 08-PAK-08b-Y				
<b>3. Date of Decision Letter:</b> 22/12/2017				
<b>4. Date of the Partnership Framework Agreement:</b> 19/05/2015				
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine				
<b>6. Vaccine type:</b> Pentavalent				
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose per vial, LIQUID				
<b>8. Programme duration<sup>11</sup>:</b> 2008 -2018				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)				
	<b>2008-2016</b>	<b>2017</b>	<b>2018</b>	<b>Total<sup>12</sup></b>
<b>Programme Budget (US\$)</b>	325,875,394 <sup>13</sup>	29,090,500	22,468,500	377,434,394
<b>10. Vaccine introduction grant (in US\$):</b> Total vaccine introduction grant of US\$1,811,000 was paid on 18 August 2010 (US\$ 811,000) and 7 February 2011 (US\$ 1,000,000).				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>14</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2008-2016</b>	<b>2017</b>	<b>2018</b>	
Number of Pentavalent vaccine doses		15,774,700	19,378,200	
Annual Amounts (US\$)	325,875,394 <sup>15</sup>	29,090,500	22,468,500	
<b>12. Procurement agency:</b> To be determined by country in compliance with the Partnership Framework Agreement.				
<b>13. Self-procurement:</b> Not applicable				
<b>14. Co-financing obligations:</b> Reference code: 1718-PAK-04a-X-C				
<b>15.</b>				
<p>According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. Following the approved Country Tailored Approach for Pakistan that allows the alignment of timings of country's co-financing requirements with its fiscal year, Pakistan is required to fulfill the following obligations covering fiscal year 2017/2018 at the latest by 30<sup>th</sup> of June 2018 and 2018/2019 by the 30<sup>th</sup> of June 2019.</p>				
<b>Type of supplies to be purchased with Country funds in each year</b>		<b>FY2017/2018</b>	<b>FY2018/2019</b>	
Number of vaccine doses		1,682,500	4,608,100	

<sup>11</sup> This is the entire duration of the Programme.

<sup>12</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>13</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>14</sup> This is the amount that Gavi has approved. The 2017 amounts have been amended.

<sup>15</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Number of AD syringes	1,766,000	4,869,000
Number of safety boxes	19,450	53,575
Value of vaccine doses (US\$)	2,986,308	4,976,658
<b>Total co-financing payments (US\$) (including freight)</b>	<b>3,192,000</b>	<b>5,563,500</b>
<b>16. Operational support for campaigns:</b> Not applicable		
<b>17. Additional reporting requirements:</b> Not applicable		
<b>Reports and other information</b>	<b>Due dates</b>	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
<b>18. Financial clarifications:</b> Not applicable		
<b>19. Other conditions:</b> Not applicable		

Signed by,  
On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 December 2017

**Decision Letter  
Financial and Programmatic information: Support for Rotavirus Vaccine**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Pakistan			
<b>2. Grant number:</b> 1718-PAK-13b-X / 17-PAK-08b-Y			
<b>3. Date of Decision Letter:</b> 22/12/2017			
<b>4. Date of the Partnership Framework Agreement:</b> 19/05/2015			
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine			
<b>6. Vaccine type:</b> Rotavirus			
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 doses schedule			
<b>8. Programme duration<sup>16</sup>:</b> 2017 -2018			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	<b>2017</b>	<b>2018</b>	<b>Total<sup>17</sup></b>
<b>Programme Budget (US\$)</b>	24,353,500 <sup>18</sup>	10,192,500	34,546,000
<b>10. Vaccine introduction grant (in US\$):</b> Total vaccine introduction grant of US\$ 5,185,454 was paid on 19 July 2017 (US\$ 2,537,695), 11 October 2017 (US\$ 1,275,318) and 21 November 2017 (US\$ 1,372,441)			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>19</sup>			
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2017</b>	<b>2018</b>	
Number of Rotavirus vaccine doses	10,830,000	4,905,000	
Annual Amounts (US\$)	24,353,500 <sup>20</sup>	10,192,500	
<b>12. Procurement agency:</b> To be determined by country in compliance with the Partnership Framework Agreement.			
<b>13. Self-procurement:</b> Not applicable			
<b>14. Co-financing obligations:</b> Reference code: 1718-PAK-13b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. Following the approved Country Tailored Approach for Pakistan that allows the alignment of timings of country's co-financing requirements with its fiscal year, Pakistan is required to fulfill the following obligations covering fiscal year 2017/2018 at the latest by 30 <sup>th</sup> of June 2018 and 2018/2019 by the 30 <sup>th</sup> of June 2019.			
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>FY2017/2018</b>	<b>FY2018/2019</b>	
Number of vaccine doses	2,506,500	3,421,500	
Value of vaccine doses (US\$)	5,487,268	6,880,418	

<sup>16</sup> This is the entire duration of the Programme.

<sup>17</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>18</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>19</sup> This is the amount that Gavi has approved. The annual amount for 2017 has been amended

<sup>20</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



<b>Total co-financing payments (US\$) (including freight)</b>	<b>5,633,500</b>	<b>7,106,000</b>
<b>15. Operational support for campaigns:</b> Not applicable		
<b>16. Additional reporting requirements:</b> Not applicable		
<b>Reports and other information</b>	<b>Due dates</b>	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
<b>17. Financial clarifications:</b> Not applicable		
<b>18. Other conditions:</b> Not applicable		

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 December 2017

**Decision Letter**  
**Financial and Programmatic information: Support for Injection Safety Devices**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Pakistan			
<b>2. Grant number:</b> 17-PAK-32a-X / 18-PAK-32a-X			
<b>3. Date of Decision Letter:</b> 22/12/2017			
<b>4. Date of the Partnership Framework Agreement:</b> 19/05/2015			
<b>5. Programme title:</b> Injection safety devices <sup>21</sup>			
<b>6. Programme duration<sup>22</sup>:</b> 2017-2018			
<b>7. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	<b>2017</b>	<b>2018</b>	<b>Total<sup>23</sup></b>
<b>Programme Budget (US\$)</b>	1,864,000	1,969,500	3,833,500
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>24</sup>			
<b>TOTAL injection safety devices to be purchased with Gavi funds in each year</b>	<b>2017</b>	<b>2018</b>	
Number of AD syringes		43,478,100	
Number of re-constitution syringes			
Number of safety boxes		478,325	
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>	<b>1,864,000</b>	<b>1,969,500</b>	
<b>Injection safety devices to be purchased with Gavi funds in each year, by type of support</b>			
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 doses per vial, LIQUID, Routine</b>			<b>2018</b>
Number of AD syringes			7,550,100
Number of re-constitution syringes			0
Number of safety boxes			83,075
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>			<b>342,000</b>
<b>New Vaccine Support (NVS), Pneumococcal (PCV10), 2 doses per vial , LIQUID, (PCV10), 4 doses per vial, LIQUID</b>			<b>2018</b>
Number of AD syringes			15,452,300
Number of re-constitution syringes			

<sup>21</sup> This does not include vaccines.

<sup>22</sup> This is the entire duration of the Programme.

<sup>23</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>24</sup> This is the amount that Gavi has approved. The annual amount for 2017 has been amended.

Number of safety boxes	170,000
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>	<b>700,000</b>
<b>New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose per vial, LIQUID</b>	
	<b>2018</b>
Number of AD syringes	20,475,700
Number of re-constitution syringes	
Number of safety boxes	225,250
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>	<b>927,500</b>
<b>9. Procurement agency:</b> UNICEF	
<b>10. Self-procurement:</b> Not applicable.	
<b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 December 2017